T-DXd plus pertuzumab sets first-line standard in HER2-positive metastatic breast cancer

The phase 3 DESTINY-Breast09 trial demonstrated that trastuzumab deruxtecan (T-DXd) plus pertuzumab significantly prolonged progression-free survival (PFS) compared with the long-standing standard-of-care, as outlined in the CLEOPATRA standard of taxane plus trastuzumab and pertuzumab (THP). Presented by Dr Sara M. Tolaney (Dana-Farber Cancer Institute and Harvard Medical School, MA, USA), the DESTINY-Breast09 global phase 3 trial (NCT04784715) randomised 1,157 participants with advanced/metastatic breast cancer 1:1:1 to T-DXd with or without pertuzumab, or standard THP [1]. The primary endpoint was PFS as assessed by blinded, independent central review in the intent-to-treat population. Other endpoints included overall survival, PFS as assessed by the investigator, objective response rate, duration of response, and safety. At the first interim analysis, participants receiving T-DXd plus per...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 July 2025